27th Nov 2008 15:08
|
For immediate release |
27 November 2008 |
ABCAM PLC
("Abcam" or "the Company")
ABCAM PLC SHARE INCENTIVE PLAN
PURCHASE OF PARTNERSHIP SHARES AND AWARDS OF MATCHING SHARES
Cambridge UK, 27 November 2008: Abcam announces that on 27 November 2008 the following executive directors of the Company purchased ordinary shares of 1p each at a cost of 485 pence per share as "Partnership Shares" under the Abcam plc Share Incentive Plan (an HMRC approved all employee share purchase plan adopted by the Company's shareholders at its AGM on 3 November 2008), as detailed below:
Jonathan Milner 309 shares
Jim Warwick 309 shares
Jeff Iliffe 309 shares
The above transactions were undertaken by the trustee of the Abcam plc Share Incentive Plan, a UK registered company, on behalf of the above individuals and the shares purchased on the London Stock Exchange.
In connection with the above purchases on the same date the executive directors were conditionally awarded ordinary shares of 1p as "matching shares" under the all employee Abcam plc Share Incentive Plan as detailed below:
Jonathan Milner 309 shares
Jim Warwick 309 shares
Jeff Iliffe 309 shares
The risk of forfeiture attached to the matching shares will normally be removed on the third anniversary of allocation subject to continued employment and the retention of the Partnership Shares in connection with which they were awarded.
No consideration was paid by the above grantees for the award of the matching shares and no consideration is due on the release of the matching shares.
For further information please contact:
|
Abcam |
+ 44 (0) 1223 696000 |
|
Jonathan Milner, Chief Executive Officer |
|
|
Jeff Iliffe, Chief Financial Officer www.abcam.com |
|
|
Numis Securities |
+ 44 (0) 20 7776 1500 |
|
Nominated Adviser - Michael Meade, Nick Westlake Corporate Broking - James Black |
|
|
Buchanan Communications |
+ 44 (0) 20 7466 5000 |
|
Mark Court / Mary-Jane Johnson |
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, UK, with a US office located in Cambridge, Massachusetts and a Japanese office in Tokyo. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third party produced antibodies to academic and commercial users throughout the world with product information provided and ordering available through the Company's website, www.abcam.com. The antibodies are sold under the Abcam brand name. The Company's vision is to build the largest online antibody resource in the world while also ensuring that the antibodies are of high quality and commercially viable. Abcam now has an online catalogue of over 47,000 products, most of which are antibodies, from over 250 suppliers supported by up-to-date and detailed technical data sheets, which are created by the Company. The Company currently employs over 200 staff in its three operating companies.
Related Shares:
ABC.L